Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference

By In The News
March 6, 2019 in The Headlines

Recommended Posts

In The News

Posted March 6, 2019

- Share

Posted March 6, 2019

WOODCLIFF LAKE, N.J., March 6, 2019 /PRNewswire/ -- Eisai announced today that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN®) following cyclin-dependent kinase (CDK) 4/6 inhibitor in community oncology practices will be...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222008
2. Jaydee
  17783
3. deicer
  13345
4. Kip Powick
  12311
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.4k
- Total Posts
  
  565k

Sign In

Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support